Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies

Cancer Science

Volumn 98, Issue 6, 2007, Pages 779-789

  Temmink, Olaf H ^a   Emura, Tomohiro ^b   de Bruin, Michiel ^a   Fukushima, Masakazu ^b   Peters, Godefridus J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 DEOXYRIBOSE; 5 BROMOURACIL; 5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; DNA; ENDOTHELIAL CELL GROWTH FACTOR; ERLOTINIB; FIBROBLAST GROWTH FACTOR; FLOXURIDINE; FLOXURIDINE PHOSPHATE; FLUOROURACIL; GEFITINIB; GLYCOSYLTRANSFERASE INHIBITOR; IRINOTECAN; OXALIPLATIN; PLATELET DERIVED GROWTH FACTOR; PURINE DERIVATIVE; RALTITREXED; TEGAFUR; THYMIDINE PHOSPHORYLASE; THYMIDINE PHOSPHORYLASE INHIBITOR; TRIFLURIDINE; UFT; UNCLASSIFIED DRUG; UNINDEXED DRUG; URACIL DERIVATIVE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BONE MARROW DEPRESSION; CANCER CELL CULTURE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLITIS; COLORECTAL CANCER; CYTOTOXICITY; DIARRHEA; DIGESTIVE SYSTEM CANCER; DOWN REGULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; EXPERIMENTAL MODEL; FATIGUE; GASTROINTESTINAL DISEASE; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LIVER METASTASIS; METASTASIS POTENTIAL; MONKEY; NAUSEA; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RASH; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TUMOR VASCULARIZATION; VOMITING;

ADMINISTRATION, ORAL; ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL AVAILABILITY; CLINICAL TRIALS; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; FORECASTING; GASTROINTESTINAL NEOPLASMS; HUMANS; PYRIMIDINES; THYMIDINE; TRIFLURIDINE; URACIL;

EID: 34247862350     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00477.x     Document Type: Review

References (80)

1. Heidelberger C, Parsons DG, Remy DC. Syntheses of 5-trifluoromethyluracil and 5-trifluoromethyl-2′-deoxyuridine. J Med Chem 1964; 55: 1-5.
2. Heidelberger C, Boohar J, Kampschroer B. Fluorinated pyrimidines. XXIV. In vivo metabolism of 5-trifluoromethyluracil-2-C-14 and 5-trifluoromethyl-2′-deoxyuridine-2-C-14. Cancer Res 1965; 25: 377-81.
3. Heidelberger C, Anderson SW. Fluorinated pyrimidines. XXI. The tumor inhibitory activity of 5-trifluoromethyl-2′-deoxyuridine. Cancer Res 1964; 24: 1979-85.
4. Ansfield FJ, Ramirez G. Phase I and II studies of 2′-deoxy-5-(trifluoromethyl)-uridine (NSC-75520). Cancer Chemother Rep 1971; 55: 205-8.
5. De Clercq E. Antiviral drugs in current clinical use. J Clin Virol 2004; 30: 115-33.
6. Carmine AA, Brogden RN, Heel RC, Speight TM, Avery GS. Trifluridine: A review of its antiviral activity and therapeutic use in the topical treatment of viral eye infections. Drugs 1982; 23: 329-53.
7. De Bruin M, Temmink OH, Hoekman K, Pinedo HM, Peters GJ. Role of platelet derived endothelial cell growth factor/thymidine phosphorylase in health and disease. Cancer Ther 2006; 4: 99-124.
8. Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 2001; 19: 2282-92.
9. Reyes P, Heidelberger C. Fluorinated pyrimidines. XXVI. Mammalian thymidylate synthetase: Its mechanism of action and inhibition by fluorinated nucleotides. Mol Pharmacol 1965; 1: 14-30.
10. Van Triest B, Peters GJ. Thymidylate synthase: A target for combination therapy and determinant of chemotherapeutic response in colorectal cancer. Oncology 1999; 57: 179-94.
11. Eckstein JW, Foster PG, Finer-Moore J, Wataya Y, Santi DV. Mechanism-based inhibition of thymidylate synthase by 5-(trifluoromethyl)-2′-deoxyuridine 5′-monophosphate. Biochemistry 1994; 33: 15 086-94.
12. Santi DV, Sakai TT. Thymidylate synthetase. Model studies of inhibition by 5-trifluoromethyl-2′-deoxyuridylic acid. Biochemistry 1971; 10: 3598-607.
13. Temmink OH, Comijn EM, Fukushima M, Peters GJ. Intracellular thymidylate synthase inhibition by trifluorothymidine in FM3A cells. Nucleosides Nucleotides Nucleic Acids 2004; 23: 1491-4.
14. Peters GJ, Backus HH, Freemantle S et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 2002; 1587: 194-205.
15. Fujiwara Y, Heidelberger C. Fluorinated pyrimidines. 38. The incorporation of 5-trifluoromethyl-2′-deoxyuridine into the deoxyribonucleic acid of vaccinia virus. Mol Pharmacol 1970; 6: 281-91.
16. Temmink OH, De Bruin M, Comijn EM, Fukushima M, Peters GJ. Determinants of trifluorothymidine sensitivity and metabolism in colon and lung cancer cells. Anticancer Drugs 2005; 16: 285-92.
17. Emura T, Nakagawa F, Fujioka A et al. An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA. Int J Mol Med 2004; 13: 249-55.
18. Emura T, Suzuki N, Yamaguchi M, Ohshimo H, Fukushima M. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. Int J Oncol 2004; 25: 571-8.
19. Inaba M, Mitsuhashi J, Sawada H et al. Reduced activity of anabolizing enzymes in 5-fluorouracil-resistant human stomach cancer cells. Jpn J Cancer Res 1996; 87: 212-20.
20. Murakami Y, Kazuno H, Emura T, Tsujimoto H, Suzuki N, Fukushima M. Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells. Int J Oncol 2000; 17: 277-83.
21. Emura T, Murakami Y, Nakagawa F, Fukushima M, Kitazato K. A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. Int J Mol Med 2004; 13: 545-9.
22. De Bruin M, van Capel T, van der Born K et al. Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity. Br J Cancer 2003; 88: 957-64.
23. Dexter DL, Wolberg WH, Ansfield FJ, Helson L, Heidelberger C. The clinical pharmacology of 5-trifluoromethyl-2′-deoxyuridine. Cancer Res 1972; 32: 247-53.
24. Takeda S, Wierzba K, Yamashita J et al. Potentiation of the antitumor activity of 5-trifluoromethyl-2′-deoxyuridine by the use of depot forms of the parent compound. Cancer Chemother Pharmacol 1992; 30: 360-4.
25. Yamashita J, Takeda S, Matsumoto H, Unemi N, Yasumoto M. Studies on antitumor agents. 8. Antitumor activities of O-alkyl derivatives of 2′-deoxy-5-(trifluoromethyl) uridine and 2′-deoxy-5-fluorouridine. J Med Chem 1989; 32: 136-9.
26. Yamashita J, Takeda S, Matsumoto H, Terada T, Unemi N, Yasumoto M. Studies on antitumor agents. VI. Syntheses and antitumor activities of acyl derivatives of 2′-deoxy-5-trifluoromethyluridine. Chem Pharm Bull (Tokyo) 1987; 35: 2090-4.
27. Peters GJ, Van Groeningen CJ, Laurensse EJ, Pinedo HM. A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa. Cancer 1991; 68: 1903-9.
28. Langen P, Etzold G, Barwolff D, Preussel B. Inhibition of thymidine phosphorylase by 6-aminothymine and derivatives of 6-aminouracil. Biochem Pharmacol 1967; 16: 1833-7.
29. Reigan P, Gbaj A, Chinje E, Stratford IJ, Douglas KT, Freeman S. Synthesis and enzymatic evaluation of xanthine oxidase-activated prodrugs based on inhibitors of thymidine phosphorylase. Bioorg Med Chem Lett 2004; 14: 5247-50.
30. Cole C, Reigan P, Gbaj A et al. Potential tumor-selective nitroimidazolylmethyluracil prodrug derivatives: Inhibitors of the angiogenic enzyme thymidine phosphorylase. J Med Chem 2003; 46: 207-9.
31. Balzarini J, Gamboa AE, Esnouf R et al. 7-Deazaxanthine, a novel prototype inhibitor of thymidine phosphorylase. FEBS Lett 1998; 438: 91-5.
32. Yano S, Kazuno H, Suzuki N et al. Synthesis and evaluation of 6-methylene-bridged uracil derivatives. Part 1: Discovery of novel orally active inhibitors of human thymidine phosphorylase. Bioorg Med Chem 2004; 12: 3431-41.
33. Yano S, Kazuno H, Sato T et al. Synthesis and evaluation of 6-methylene-bridged uracil derivatives. Part 2: Optimization of inhibitors of human thymidine phosphorylase and their selectivity with uridine phosphorylase. Bioorg Med Chem 2004; 12: 3443-50.
34. Fukushima M, Suzuki N, Emura T et al. Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2′-deoxyribonucleosides. Biochem Pharmacol 2000; 59: 1227-36.
35. Emura T, Suzuki N, Fujioka A, Ohshimo H, Fukushima M. Potentiation of the antitumor activity of alpha, alpha, alpha-trifluorothymidine by the co-administration of an inhibitor of thymidine phosphorylase at a suitable molar ratio in vivo. Int J Oncol 2005; 27: 449-55.
36. Ellis LM. Angiogenesis and its role in colorectal tumor and metastasis formation. Semin Oncol 2004; 31: 3-9.
37. Ishigami SI, Arii S, Furutani M et al. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer 1998; 78: 1379-84.
38. Manetti F, Botta M. Small-molecule inhibitors of fibroblast growth factor receptor (FGFR) tyrosine kinases (TK). Curr Pharm Des 2003; 9: 567-81.
39. George D. Platelet-derived growth factor receptors: A therapeutic target in solid tumors. Semin Oncol 2001; 28: 27-33.
40. Miyazono K, Okabe T, Urabe A, Takaku F, Heldin CH. Purification and properties of an endothelial cell growth factor from human platelets. J Biol Chem 1987; 262: 4098-103.
41. Ackland SP, Peters GJ. Thymidine phosphorylase: Its role in sensitivity and resistance to anticancer drugs. Drug Resist Updat 1999; 2: 205-14.
42. Moghaddam A, Bicknell R. Expression of platelet-derived endothelial cell growth factor in Escherichia coli and confirmation of its thymidine phosphorylase activity. Biochemistry 1992; 31: 12 141-6.
43. Moghaddam A, Zhang HT, Fan TP et al. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA 1995; 92: 998-1002.
44. Haraguchi M, Miyadera K, Uemura K et al. Angiogenic activity of enzymes. Nature 1994; 368: 198.
45. Takebayashi Y, Yamada K, Miyadera K et al. The activity and expression of thymidine phosphorylase in human solid tumours. Eur J Cancer 1996; 32A: 1227-32.
46. Takebayashi Y, Akiyama S, Akiba S et al. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 1996; 88: 1110-17.
47. Van Triest B, Pinedo HM, Blaauwgeers JL et al. Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer. Clin Cancer Res 2000; 6: 1063-72.
48. Takahashi Y, Bucana CD, Liu W et al. Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: Role of infiltrating cells. J Natl Cancer Inst 1996; 88: 1146-51.
49. Takahashi Y, Ellis LM, Mai M. The angiogenic switch of human colon cancer occurs simultaneous to initiation of invasion. Oncol Rep 2003; 10: 9-13.
50. Amaya H, Tanigawa N, Lu C et al. Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer. Cancer Lett 1997; 119: 227-35.
51. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005; 23: 3706-12.
52. Zondor SD, Medina PJ. Bevacizumab: An angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother 2004; 38: 1258-64.
53. Uchimiya H, Furukawa T, Okamoto M et al. Suppression of thymidine phosphorylase-mediated angiogenesis and tumor growth by 2-deoxy-L-ribose. Cancer Res 2002; 62: 2834-9.
54. Ikeda R, Furukawa T, Kitazono M et al. Molecular basis for the inhibition of hypoxia-induced apoptosis by 2-deoxy-D-ribose. Biochem Biophys Res Commun 2002; 291: 806-12.
55. Akiyama S, Furukawa T, Sumizawa T et al. The role of thymidine phosphorylase, an angiogenic enzyme, in tumor progression. Cancer Sci 2004; 95: 851-7.
56. Matsushita S, Nitanda T, Furukawa T et al. The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors. Cancer Res 1999; 59: 1911-6.
57. Takao S, Akiyama SI, Nakajo A et al. Suppression of metastasis by thymidine phosphorylase inhibitor. Cancer Res 2000; 60: 5345-8.
58. Sato J, Sata M, Nakamura H et al. Role of thymidine phosphorylase on invasiveness and metastasis in lung adenocarcinoma. Int J Cancer 2003; 106: 863-70.
59. Endo M, Shinbori N, Fukase Y et al. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5′-deoxy-5-fluorouridine by cyclophosphamide in mammary tumor models. Int J Cancer 1999; 83: 127-34.
60. Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 2001; 19: 4097-106.
61. Temmink OH, Prins HJ, Van Gelderop E, Peters GJ. The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells. Br J Cancer 2007; 96: 61-6.
62. Temmink OH, de Bruin M, Turksma AW, Cricca S, Laan AC, Peters GJ. Activity and substrate specificity of pyrimidine phosphorylases and their role in fluoropyrimidine sensitivity in colon cancer cell lines. Int J Biochem Cell Biol 2007; 39: 565-75.
63. Temmink OH, De Bruin M, Laan AC et al. The role of thymidine phosphorylase and uridine phosphorylase in (fluoro) pyrimidine metabolism in peripheral blood mononuclear cells. Int J Biochem Cell Biol 2006; 38: 1759-65.
64. Cao D, Pizzorno G. Uridine phosphorylase: An important enzyme in pyrimidine metabolism and fluoropyrimidine activation. Drugs Today (Barc) 2004; 40: 431-43.
65. Temmink OH, Hoogeland MF, Fukushima M, Peters GJ. Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells. Cancer Chemother Pharmacol 2006; 57: 171-9.
66. Temmink OH, Hoebe EK, van der Born K, Ackland SP, Fukushima M, Peters GJ. Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells. Br J Cancer 2007; 96: 231-40.
67. Temmink OH, Hoebe EK, Fukushima M, Peters GJ. Irinotecan-induced cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidine. Eur J Cancer 2007; 43: 175-83.
68. Peters GJ, Schornagel JH, Milano GA. Clinical pharmacokinetics of anti-metabolites. Cancer Surv 1993; 17: 123-56.
69. Pouremad R, Bahk KD, Shen YJ, Knop RH, Wyrwicz AM. Quantitative 19F NMR study of trifluorothymidine metabolism in rat brain. NMR Biomed 1999; 12: 373-80.
70. Pugmire MJ, Ealick SE. Structural analyses reveal two distinct families of nucleoside phosphorylases. Biochem J 2002; 361: 1-25.
71. Tsuchiya H, Kuwata K, Nagayama S, Yamashita K, Kamiya H, Harashima H. Pharmacokinetic modeling of species-dependent enhanced bioavailability of trifluorothymidine by thymidine phosphorylase inhibitor. Drug Metab Pharmacokinet 2004; 19: 206-15.
72. Maehara Y, Nakamura H, Nakane Y et al. Activities of various enzymes of pyrimidine nucleotide and DNA syntheses in normal and neoplastic human tissues. Gann 1982; 73: 289-98.
73. Gordon HL, Bardos TJ, Chmielewicz ZF, Ambrus JL. Comparative study of the thymidine kinase and thymidylate kinase activities and of the feedbach inhibition of thymidine kinase in normal and neoplastic human tissue. Cancer Res 1968; 28: 2068-77.
74. Emura T, Nakagawa F, Fujioka A, Ohshimo H, Kitazato K. Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model. Oncol Rep 2004; 11: 381-7.
75. Hong DS, Abbruzzese JL, Bogaard K et al. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. Cancer 2006; 107: 1383-90.
76. Dwivedy S, Hoff PM, Dumas P et al. Safety and pharmacokinetics (PK) of an antitumor/antiangiogenic agent, TAS-102: A phase I study for patients (PTS) with solid tumors. Proc Am Soc Clin Oncol 2001; 20: Abstract 386.
77. Thomas MB, Hoff PM, Carter S et al. A dose-finding, safety and pharmacokinetics study of TAS-102, an antitumor/antiangiogenic agent given orally on a once-daily schedule for five days every three weeks in patients with solid tumors. Proc Am Assoc Cancer Res 2002; 43: Abstract 2754.
78. Green MC, Pusztai L, Theriault RL et al. Phase I study to determine the safety of oral administration of TAS-102 on a twice daily (BID) schedule for five days a week (wk) followed by two days rest for two wks, every (Q) four wks in patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2006; 25: Abstract 10 576.
79. Wildiers H, Guetens G, De Boeck G et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 2003; 88: 1979-86.
80. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 2004; 4: 806-13.